400G ultra low latency 56/112G FEC and SERDES IP sub 10ns latency
TSMC Board Approves Capital Appropriation for 65nm and 90nm Capacity
TSMC Spokesperson and Vice President Ms. Lora Ho said other major conclusions of the Board meeting were as follows:
1. Approved capital appropriation of US$9.2 million to expand 1.0 micron high voltage process capacity in Fab 2.
2. Approved the purchase of an additional 6.8% of shares in Systems on Silicon Manufacturing Company Pte. Ltd. (SSMC) at a price of approximately US$73 million. TSMC will own 38.8% of SSMC after the purchase.
3. Approved capital increase of NT$24,828,340 to reflect the issuance of 2,482,834 new TSMC common shares as a result of employees exercising their stock options between July 1 and September 30, 2006. Subsequent to such capital increase, the registered paid-in capital of TSMC will be NT$258,258.4 million.
|
Related News
- TSMC Board of Directors Approves Capital Appropriation for Expanding Capacities
- TSMC Board Approves Expansion of 45 Nanometer Capacity
- ARM Announces The Release Of Multiple Standard Cell Libraries On TSMC 90nm and 65nm Processes
- Accellera Board Approves Universal Verification Methodology for Mixed-Signal (UVM-MS) 1.0 Standard for Release
- TSMC Announces Dr. Mark Liu Not to Participate in Next Board of Directors Election
Breaking News
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- Keysom Unveils Keysom Core Explorer V1.0
Most Popular
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- Ceva, Inc. Announces First Quarter 2025 Financial Results
- Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design
![]() |
E-mail This Article | ![]() |
![]() |
Printer-Friendly Page |